Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

AZD6234

This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight

AstraZeneca · Phase 2 · Active, not recruiting · Enrollment 16

NCT07017179

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
AZD6234 (sub-study 1)n/rn/rn/rn/r
Placebo (sub-study 1)n/rn/rn/rn/r
AZD9550(sub-study 2 Cohort A)n/rn/rn/rn/r
Placebo (sub-study 2 Cohort A)n/rn/rn/rn/r
AZD6234 in combination with AZD9550 (sub-study 2 Cohort B)n/rn/rn/rn/r
Placebo (sub-study 2 Cohort B)n/rn/rn/rn/r

Not shown

  • AZD6234 (sub-study 1): endpoint not reported
  • Placebo (sub-study 1): endpoint not reported
  • AZD9550(sub-study 2 Cohort A): endpoint not reported
  • Placebo (sub-study 2 Cohort A): endpoint not reported
  • AZD6234 in combination with AZD9550 (sub-study 2 Cohort B): endpoint not reported
  • Placebo (sub-study 2 Cohort B): endpoint not reported